Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in locally advanced or metastatic epithelial tumors Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Squamous Cell
  • Head and Neck Neoplasms
  • Immunoglobulin G
  • Receptor, Epidermal Growth Factor
  • Receptor, ErbB-3

abstract

  • MEHD7945A was well-tolerated as single agent with evidence of tumor pharmacodynamic modulation and antitumor activity in SCCHN. Phase II studies were initiated with flat (nonweight-based) dosing at 1,100 mg q2w in SCCHN and colorectal cancer.

publication date

  • June 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-14-2412

PubMed ID

  • 26034219

Additional Document Info

start page

  • 2462

end page

  • 70

volume

  • 21

number

  • 11